Saturday 17 October 2026 Export ELUT’s income statement to Excel — free account

Elutia Inc.

In the quarter to June 2026, revenue fell 11.7%, EPS grew 26.1% and free cash flow fell 2.52%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.79 0.00 0.00%

Follow ELUT

Alert me

Market cap: $34.9M
P/E: 0.6×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 5/9
Altman Z: −4.10
Beneish M: 0.81
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.24

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	3	6	3	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 20.04%

Capital & Financial Ratios $m

Market Cap 34.93

Revenue 12.14

Net Income 51.81

Free Cash Flow (46.03)

Net Debt (19.90)

Current Ratio 1.77

Debt/Equity 0.00

P/E ratio 0.64

Fwd P/E (1.66)

P/S ratio 2.88

P/B ratio 2.22

Past 5Y EPS Growth —

This Y EPS Growth (172.41%)

Next Y EPS Growth 14.29%

Next Y revenue growth (38.99%)

Next 5Y EPS Growth 41.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 51.89%

10-year low 10-year high

EV/Sales against its own 10 years 54.57%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	19	13	36	20
Receivables	6	7	15	13
Inventory	4	2	3	3
Other	—	2	—	—
	31	26	56	37

	2023	2024	2025	Q'26
Payables	3	4	5	4
ST’ Debt	3	1	—	—
Other	27	25	16	12
	43	38	25	21

Compound Annual Growth %

	10y	5y	3y
Sales	—	(22.04%)	(19.82%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	5.84%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	3	2	—	—	—
’25	3	3	3	3	12
’24	7	6	4	—	14
’23	6	6	6	6	25
’22	11	13	6	(6)	24
’21	13	12	11	11	47
’20	10	9	12	12	43

Fiscal quarters ending in the months shown.

value withheld pending a data check

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(8)	—	—	—
’25	(9)	(8)	(3)	(25)	(45)
’24	(3)	(4)	(3)	(12)	(23)
’23	(5)	(2)	(5)	(9)	(22)
’22	(7)	(3)	(6)	(5)	(21)
’21	(5)	(1)	(3)	(6)	(15)
’20	(3)	(4)	(1)	(5)	(14)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(8)	(9)	—	—	—
’25	(9)	(8)	(4)	(26)	(47)
’24	(3)	(4)	(4)	(12)	(23)
’23	(5)	(2)	(5)	(9)	(22)
’22	(7)	(4)	(6)	(5)	(22)
’21	(5)	(1)	(3)	(6)	(16)
’20	(3)	(4)	(2)	(5)	(14)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.17)	(0.17)	—	—	—
’25	(0.21)	(0.26)	(0.19)	1.48	0.87
’24	(0.75)	(1.13)	(0.33)	(0.26)	(1.86)
’23	(0.49)	(0.65)	(0.57)	(0.40)	(2.07)
’22	(0.60)	(0.69)	(0.73)	(0.38)	(2.38)
’21	(0.50)	(0.23)	(0.81)	(0.82)	(2.38)
’20	(7.04)	(7.99)	(15.79)	(0.57)	(8.88)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	10.55	4.10	3.37	1.10	2.16	0.50	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	18.00	18.20	9.01	5.38	5.24	3.80
People
People	Employees	—	—	—	151	163	176	164	54	51	26
	Revenue/emp, $m	—	—	0.00	0.28	0.26	0.27	0.15	0.46	0.28	0.47
Income, $m
Income, $m	Revenue	—	—	39	43	43	47	24	25	14	12
	Gross margin, %	—	—	40.84	46.08	48.17	40.14	48.80	44.67	46.42	53.66
	EBT	—	—	(12)	(12)	(22)	(25)	(36)	(41)	(45)	(16)
	EBT margin, %	—	—	(29.56)	(27.76)	(51.07)	(52.28)	(151.57)	(166.58)	(313.39)	(129.00)
	Net income	—	0	(12)	(12)	(22)	(25)	(33)	(38)	(54)	53
	Depreciation	—	—	4	4	4	4	4	4	3	3
Per share, $
Per share, $	Revenue	—	—	62.01	66.41	14.96	4.54	1.72	1.36	0.50	0.30
	Earnings	—	—	(18.37)	(18.48)	(8.88)	(2.38)	(2.38)	(2.07)	(1.86)	1.29
	Cash flow	—	—	(8.65)	(11.18)	(4.78)	(1.48)	(1.55)	(1.20)	(0.78)	(1.08)
	Capex	—	—	(0.30)	(0.89)	(0.22)	(0.04)	(0.04)	(0.02)	(0.02)	(0.05)
	Free cash flow	—	—	(8.95)	(12.08)	(5.00)	(1.51)	(1.59)	(1.22)	(0.80)	(1.13)
	Book value	—	—	(68.95)	(85.31)	7.30	1.29	(0.36)	(2.13)	(1.59)	0.67
	Shares, m	—	—	1	1	3	10	14	18	29	41
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.56
	P/S	—	—	0.00	0.00	3.00	1.39	2.34	1.83	7.52	2.32
	P/B	—	—	0.00	0.00	6.15	4.87	0.00	0.00	0.00	1.03
	EV/Sales	—	—	0.00	0.00	2.64	1.14	3.18	2.01	8.25	1.49
	EV/FCF	—	—	(7.00)	(7.00)	(7.89)	(3.40)	(3.45)	(2.25)	(5.12)	(0.39)
Cash, $m
Cash, $m	Operating cash flow	—	—	(5)	(7)	(14)	(15)	(21)	(22)	(23)	(45)
	Capex	—	—	0	(1)	(1)	0	(1)	0	(1)	(2)
	Free cash flow	—	—	(6)	(8)	(14)	(16)	(22)	(22)	(23)	(47)
Balance, $m
Balance, $m	Working capital	—	—	5	0	33	21	8	(12)	(12)	31
	Total debt	—	—	18	21	24	18	37	24	24	—
	Net debt	—	—	15	19	(15)	(12)	20	4	11	(36)
	Shareholders’ equity	—	—	(43)	(55)	21	14	(5)	(39)	(46)	28
Returns, %
Returns, %	ROA	—	—	(48.45)	(25.81)	(39.72)	(33.11)	(48.37)	(67.08)	(135.63)	108.41
	ROIC	—	—	0.00	0.00	(156.82)	(921.57)	(146.02)	0.00	0.00	0.00
	ROE	—	—	23.48	24.24	147.81	(144.57)	(775.14)	172.60	127.15	(574.35)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
NNOX Nano-X Imaging Ltd.	$38.6M	— (loss-making)	— (loss-making)	+36.71% (above 0%: growing)	n/m	−21.37% (below 0%: shrinking)	(1,050.87%)	(1,334.91%)	Compare
CVRX CVRx, Inc.	$37.0M	— (loss-making)	— (loss-making)	+15.57% (above 0%: growing)	n/m	−11.18% (below 0%: shrinking)	87.39%	(82.92%)	Compare
ELUT Elutia Inc.	$34.9M	0.6×	— (loss-making)	−11.65% (below 0%: shrinking)	n/m	−2.52% (below 0%: shrinking)	59.62%	(327.85%)
QTI QT Imaging Holdings, Inc.	$34.8M	— (loss-making)	— (loss-making)	+103.20% (above 0%: growing)	n/m	−236.31% (below 0%: shrinking)	41.16%	(25.07%)	Compare
NSYS Nortech Systems Incorporated	$29.5M	27.9×	17.5×	+9.34% (above 0%: growing)	−8.33% (below 0%: shrinking)	−1,567.16% (below 0%: shrinking)	17.00%	1.86%	Compare
ITOC iTonic Holdings Ltd.	$29.3M	—	—	—	—	—	—	—	Compare
Median of peers	$37.8M	—	—	+10.91%	—	−23.97%	41.16%	(39.81%)

All 149 Medical Devices stocks →

Elutia Inc. (ELUT) key facts

Elutia Inc. (ELUT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, ELUT traded at $0.79, a market capitalization of $34.9 million.
Return on equity was −574.4% and debt-to-equity 0.00.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.10 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.